磷脂酰肌醇蛋白聚糖-3靶向治疗肝细胞癌的研究进展
投稿时间:2023-07-21  修订日期:2023-08-15  点此下载全文
引用本文:方宇昕,李育,刘宝姝,董国强.磷脂酰肌醇蛋白聚糖-3靶向治疗肝细胞癌的研究进展[J].药学实践杂志,2023,41(10):586~593
摘要点击次数: 68
全文下载次数: 63
作者单位E-mail
方宇昕 海军军医大学药学系, 上海 200433  
李育 海军军医大学药学系, 上海 200433  
刘宝姝 海军军医大学药学系, 上海 200433  
董国强 海军军医大学药学系, 上海 200433 dgq-81@163.com 
中文摘要:肝癌是全球第二大癌症死亡原因,而肝细胞癌(HCC)是最常见的原发性肝癌形式。磷脂酰肌醇蛋白聚糖-3(GPC3)是一种细胞膜表面蛋白多糖,其在正常成人组织中几乎不表达,但在肝细胞癌中特异性表达上调,因此,GPC3成为肝细胞癌诊断和治疗的可靠靶点。综述了GPC3通过Wnt、YAP、hedgehog等信号通路调节癌症发展,总结了单克隆抗体、双特异性抗体、肿瘤疫苗、免疫毒素、CAR-T细胞、光敏剂治疗等GPC3靶向治疗方法,并对未来基于GPC3的肝细胞癌治疗策略进行展望。
中文关键词:肝细胞癌  磷脂酰肌醇蛋白聚糖-3  信号通路  肝细胞癌治疗
 
Research Progress on Glypican-3 Targeted Therapy in Hepatocellular Carcinoma
Abstract:Liver cancer is the second leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) being the most common form of primary liver cancer. Glypican-3 (GPC3) is a cell membrane proteoglycan which is rarely expressed in normal adult tissues but is specifically upregulated in HCC, which makes GPC3 a reliable target for the diagnosis and treatment of HCC. The role of GPC3 in the regulation of cancer development through Wnt, YAP, hedgehog and other signaling pathways were reviewed in this article. GPC3-targeted therapies, such as monoclonal antibodies, bispecific antibodies, tumor vaccines, immunotoxins, CAR-T cells, and photosensitizer therapy were also summarized. These treatment methods offered promising approaches for HCC treatment and future treatment strategies for HCC based on GPC3 were prospected in this paper.
keywords:Hepatocellular carcinoma  Glypican-3  signaling pathway  HCC therapy
查看全文  查看/发表评论  下载PDF阅读器
关闭

分享按钮